Thermosensitive Liposome Formulation Research Articles

MRI contrast variation of thermosensitive magnetoliposomes triggered by focused ultrasound: a tool for image-guided local drug delivery

Improved drug delivery control during chemotherapy has the potential to increase the therapeutic index. MRI contrast agent such as iron oxide nanoparticles can be co-encapsulated with drugs in nanocarrier liposomes allowing their tracking and/or visualization by MRI. Furthermore, the combination of a thermosensitive liposomal formulation with an external source of heat such as high intensity focused ultrasound guided by MR temperature mapping allows the controlled local release of the content of the liposome. MRI-guided high-intensity focused ultrasound (HIFU), in combination represents a noninvasive technique to generate local hyperthermia for drug release. In this study we used ultrasmall superparamagnetic iron oxide nanoparticles (USPIO) encapsulated in thermosensitive liposomes to obtain thermosensitive magnetoliposomes (TSM). The transverse and longitudinal relaxivities of this MRI contrast agent were measured upon TSM membrane phase transition in vitro using a water bath or HIFU. The results showed significant differences for MRI signal enhancement and relaxivities before and after heating, which were absent for nonthermosensitive liposomes and free nanoparticles used as controls. Thus, incorporation of USPIO as MRI contrast agents into thermosensitive liposomes should, besides TSM tumor accumulation monitoring, allow the visualization of TSM membrane phase transition upon temperature elevation. In conclusion, HIFU under MR image guidance in combination with USPIO-loaded thermosensitive liposomes as drug delivery system has the potential for a better control of drug delivery and to increase the drug therapeutic index.

Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes

Thermosensitive liposomes (TSL) are a promising tool for triggered drug delivery in combination with local hyperthermia. Objective of this study was to investigate the influence of serum on TSL in more detail and to identify serum components which are responsible for increasing drug release. Four different formulations were investigated: DPPC/DSPC/1,2-dipalmitoyl-sn-glycero-3-phosphodiglycerol (DPPG2) 50/20/30 (mol/mol) (DPPG2-TSL); DPPC/DSPC/DPPG2/DSPE-PEG2000 50/15/30/5 (mol/mol) (DPPG2/PEG-TSL), DPPC/P-Lyso-PC/DSPE-PEG2000 90/10/4 (mol/mol) (PEG/Lyso-TSL), and DPPC/DSPC/DSPE-PEG2000 80/15/5 (mol/mol) (PEG-TSL). DPPG2-TSL was the only formulation which was unaffected by osmotic stress. All formulations tested were influenced by serum components but the susceptibility was depended on the lipid composition of the vesicle. Presence of albumin (HSA) or cholesterol-containing lipid vesicles (DPPC/Chol-LLV) increased the membrane permeability for all tested formulations at temperatures around and above Tm in a concentration based manner. PEGylation was not able to prevent the observed effect. PEG-TSL and PEG/Lyso-TSL were more susceptible to DPPC/Chol-LLV than DPPG2-containing TSL. In contrast, immunoglobulin type G (IgG) affected only anionic formulations. The membrane of DPPG2-TSL and DPPG2/PEG-TSL was more susceptible toward IgG as compared to HSA. DPPG2-TSL and PEG/Lyso-TSL were differentially influenced by fetal calf serum (FCS). As DPPG2-TSL was stabilized by pre-incubation with FCS at 37°C, this was the opposite for PEG/Lyso-TSL which were destabilized under these conditions. Individual serum components were unable to mimic the complex situation in full serum. Hence, the use of plasma or serum is still inevitable to investigate stability and release properties of novel TSL formulations until all serum components have been identified that alter TSL integrity.

Near-Infrared Image-Guided Delivery and Controlled Release Using Optimized Thermosensitive Liposomes

To engineer optimized near-infrared (NIR) active thermosensitive liposomes to potentially achieve image-guided delivery of chemotherapeutic agents. Thermosensitive liposomes were surface-coated with either polyethylene glycol or dextran. Differential scanning calorimetry and calcein release studies were conducted to optimize liposomal release, and flow cytometry was employed to determine the in vitro macrophage uptake of liposomes. Indocyanine green (ICG) was encapsulated as the NIR dye to evaluate the in vivo biodistribution in tumor-bearing mice. The optimized thermosensitive liposome formulation consists of DPPC, SoyPC, and cholesterol in the 100:50:30 molar ratio. Liposomes with dextran and polyethylene glycol demonstrated similar thermal release properties; however in vitro macrophage uptake was greater with dextran. Non-invasive in vivo NIR imaging showed tumor accumulation of liposomes with both coatings, and ex vivo NIR imaging correlated well with actual ICG concentrations in various organs of healthy mice. The optimized thermosensitive liposome formulation demonstrated stability at 37°C and efficient burst release at 40 and 42°C. Dextran exhibited potential for application as a surface coating in thermosensitive liposome formulations. In vivo studies suggest that liposomal encapsulation of ICG permits reliable, real-time monitoring of liposome biodistribution through non-invasive NIR imaging.

MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome

Non-invasive in vivo imaging of drug distribution enables real-time monitoring and prediction of therapeutic responses to treatment. We have developed a thermosensitive liposomal formulation (HaT: Hyperthermia-activated-cytoToxic) consisting of DPPC and Brij78, a formulation that enhanced drug delivery compared to the lyso-lipid temperature sensitive liposomes (LTSL). Here we report the development of a multifunctional HaT liposome co-encapsulating Gd-DTPA (an MRI probe) and doxorubicin (DOX), which simultaneously releases and reports on drug delivery in a locally heated tumor. The temperature-dependent release profiles of DOX from HaT were closely related to the change in the MR T1 relaxation time, in which DOX was 100% released at 40–42 °C in 3 min, accompanied by a 60% reduction in T1. By T1 relaxometry analysis, no Gd-DTPA leakage was detected in 30 min at 30–37 °C. In the in vivo study, DOX uptake in the tumor was quantitatively correlated with T1 response (R2 = 0.98) and the patterns of the T1 image and the intratumoral DOX uptake were matched, in which both signals were predominantly detected in the highly perfused tumor periphery. Finally, the extent of T1 relaxation enhancement in the heated tumor successfully predicted the antitumor efficacy in a standard pharmacological response model (R2 = 0.98).

Efficient tumor regression by a single and low dose treatment with a novel and enhanced formulation of thermosensitive liposomal doxorubicin

We have developed a novel and simplified thermosensitive liposomal formulation (HaT: Hyperthermia- activated cyto Toxic) composed of DPPC lipid and Brij78 (96:4, molar ratio). The HaT nanoparticles were loaded with doxorubicin (DOX) with > 95% efficiency when a pH gradient method and a drug/lipid ratio of 1/20 (w/w) were applied. Drug release from the HaT formulation was significantly faster at 40–41 °C (100% release in 2–3 min) with 3.4-fold increased membrane permeability compared to the LTSL (lyso-lipid temperature sensitive liposomes; DPPC: MSPC: DSPE-PEG 2000 = 86:10:4, molar ratio), a formulation that is currently in clinical trials. Both formulations displayed similar stability at 37 °C in serum (10–20% release in 30 min), which corresponds to their comparable pharmacokinetics in the unheated mice. An approximately 1.4-fold increased drug delivery to the locally heated tumor (~ 43 °C) was detected with HaT–DOX compared to LTSL–DOX. Moreover, when compared with free DOX, HaT enhanced drug uptake in the heated tumor by 5.2-fold and reduced drug delivery to the heart by 15-fold. A single i.v. treatment with HaT–DOX at 3 mg DOX/kg in combination with localized hyperthermia demonstrated enhanced tumor regression compared to LTSL–DOX and free DOX, and exhibited little toxicity.

In vitro stability and content release properties of phosphatidylglyceroglycerol containing thermosensitive liposomes

Recently, we reported that 1,2-dipalmitoyl- sn-glycero-3-phosphoglyceroglycerol (DPPGOG) prolongs the circulation time of thermosensitive liposomes (TSL). Since the only TSL formulation in clinical trials applies DSPE-PEG2000 and lysophosphatidylcholine (P-lyso-PC), the objective of this study was to compare the influence of these lipids with DPPGOG on in vitro stability and heat-induced drug release properties of TSL. The content release rate was significantly increased by incorporating DPPGOG or P-lyso-PC in TSL formulations. DPPC/DSPC/DPPGOG 50:20:30 (m/m) and DPPC/P-lyso-PC/DSPE-PEG2000 90:10:4 (m/m) did not differ significantly in their release rate of carboxyfluorescein with > 70% being released within the first 10s at their phase transition temperature. Furthermore, DPPC/DSPC/DPPGOG showed an improved stability at 37 °C in serum compared to the PEGylated TSL. The in vitro properties of DPPGOG-containing TSL remained unchanged when encapsulating doxorubicin instead of carboxyfluorescein. The TSL retained 89.1 ± 4.0% of doxorubicin over 3 h at 37 °C in the presence of serum. The drug was almost completely released within 120s at 42 °C. In conclusion, DPPGOG improves the in vitro properties in TSL formulations compared to DSPE-PEG2000, since it not only increases the in vivo half-life, it even increases the content release rate without negative effect on TSL stability at 37 °C which has been seen for DSPE-PEG2000/P-lyso-PC containing TSL.

Short communication: Thermosensitive liposomal taxol formulation: heatmediated targeted drug delivery in murine melanoma

Taxol, an antitumour alkaloid which stabilizes microtubules, demonstrates marked activity against several tumours. However, due to its low aqueous solubility, Cremophor EL (polyoxyethylated castor oil) is used as the excipient in pharmaceutical drug preparations of taxol. This has toxic side effects, thereby limiting the clinical use of taxol in cancer therapy. The aim of this study was to design a novel taxol formulation using thermosensitive liposomes in order to eliminate the Cremophor EL vehicle and improve the antitumour activity of taxol by site-specific drug delivery. Temperature-sensitive liposomes encapsulating taxol were prepared using the natural lipids egg phosphatidylcholine and cholesterol in combination with ethanol. The liposomes have a phase transition temperature (Tm) of 43 degrees C. The in vivo efficacy of thermosensitive liposome encapsulated taxol was determined in B16F10 murine melanoma transplanted into C57BI/6 mice in combination with local hyperthermia. A significant reduction in tumour volume and an increase in survival time was observed in tumour-bearing mice treated with a combination of hyperthermia and thermosensitive liposome encapsulated taxol compared with animals treated with an equivalent dose of free taxol with or without hyperthermia. These results suggest that thermosensitive liposome encapsulated taxol in combination with hyperthermia may be useful in improving the therapeutic efficacy of taxol in the treatment of melanoma.